Navigation Links
Avantium Appoints Gunnar Staaf as CEO Pharma

AMSTERDAM, December 16 /PRNewswire/ -- Today, Avantium announced the appointment of Gunnar Staaf as Chief Executive Officer of its pharmaceutical business. Gunnar Staaf previously worked at Serentis Ltd, Astellas Pharma, Novartis and Eli Lilly & Company, in a range of commercial and executive positions. The appointment is an important step in Avantium's plan to spin-out its pharmaceutical business. The company intends to create a stand-alone pharmaceutical company based on its offering of proprietary crystallization services and systems to customers in the pharmaceutical and biotechnology sector as well as the development of improved forms of existing drugs. After the spin-out of its pharmaceutical business, Avantium will focus on its cleantech and chemicals activities, including its Furanics bioplastics and biofuels program and offering of high-throughput catalysis services & systems.

Tom van Aken, CEO of Avantium, commented: "With his background in the pharmaceutical industry and wealth of commercial experience, Gunnar is a tremendous addition to our company. The appointment of Gunnar is an important step towards a focused pharmaceutical company. Under Gunnar's leadership we believe that our Pharma business will accelerate the development of improved drug forms, and will further strengthen our position as a leading solid-state research services & systems provider."

Upon his appointment Gunnar Staaf commented: "I am pleased to join Avantium at this exciting stage. The company has an excellent technological position and expertise in crystallization research and is a leading provider of services & systems in this area. The technology forms a strong basis for the development of novel forms and formulations of existing drugs. I am convinced that we have all the ingredients to become a dedicated and successful pharmaceutical company."

About Avantium

Avantium is a leading technology company in the area of advanced high-throughput R&D operating in the energy, chemicals and pharmaceutical industries. The company develops products and processes in the area of biofuels, bio-based chemicals and novel crystal forms of existing drugs by applying its proprietary, high-throughput R&D technology.

Avantium has demonstrated the potential of this technology by providing R&D services and tools to more than 70 companies worldwide. Avantium's customer base includes many of the world's largest energy, chemicals and pharmaceutical companies, such as BP, Shell, Sasol, Pfizer and GSK. Avantium has more than 100 employees; its offices and head quarters are based in Amsterdam, The Netherlands.

For more information

Please visit our website

SOURCE Avantium

SOURCE Avantium
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors
2. Millstone Medical Outsourcing Appoints New Leadership of Memphis Facility
3. Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer
4. Jazz Pharmaceuticals Appoints Kathryn Falberg as Chief Financial Officer
5. Patient Safety Technologies, Inc. Appoints Marc L. Rose, CPA (PA), Chief Financial Officer
6. NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
7. Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors
8. Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing
9. NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates
10. Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors
11. Company Appoints New SVP, Marketing for PBM Business
Post Your Comments:
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s ... the world, and the most handsome men, look naturally attractive. Plastic surgery should ...
Breaking Medicine News(10 mins):